Frontlight ResearchEarly access
SuspendedNo phase
CLEANer Aspiration for Pulmonary Embolism
Key facts
- Who runs it
- Argon Medical Devices
- Where
- Aurora, Bartlesville, Cincinnati, Cleveland, Dallas, Fort Lauderdale, Humble, Indianapolis, Las Vegas, Plano, Tampa, Toledo, Washington D.C., and Worcester, United StatesSee the 14 sites
- Trial code
- Status
- Suspended
- People taking part
- 125 people, planned
- Started
- 3 Jan 2025
- Expected to end
- 2 Feb 2029
- Type of study
- Interventional
- Treatments tested
- Cleaner Pro Thrombectomy System
- Record updated
- 21 October 2026
- Why it stopped
- Enrollment in the study administratively paused pending modifications to the study device design
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- At least 18 years of age at the time of consent
- Clinical signs, symptoms, and presentation consistent with acute PE
- Onset of PE symptoms occurred within 14 days of presentation
- Filling defect in at least one main or lobar pulmonary artery evidenced by CTA
- RV dysfunction on CTA or echocardiography defined as RV/LV ratio >0.9
Who cannot take part
- tPA use within 14 days prior to baseline CTA
- Cardiovascular or pulmonary surgery within last 7 days
- Presentation of PE with paradoxical emboli which may be diagnosed by concurrent stroke or concurrent arterialization
- Diagnosis of pulmonary hypertension primary type I or CTEPH; if patient does not have diagnosis of pulmonary hypertension but peak PA >70 mmHg by right heart catheterization or elevated main pulmonary artery to aorta ratio (MPA:A), up to investigator discretion
- History of severe or chronic pulmonary hypertension
- History of heparin-induced thrombocytopenia (HIT)
- Recent (within six months) history of stroke, transient ischemic attack (TIA), or intracranial bleeding
- Recent (within one month) history of active bleeding from a major organ
- Major trauma such as head trauma, or other active intracranial, or intraspinal disease within 14 days
- Cancer which requires active chemotherapy
- Patients who present with cardiac arrest and/or are on extracorporeal membrane oxygenation (ECMO) or ECMO required to perform interventional procedure
- Patients with known coagulation disorders such as antiphospholipid, Protein C, and Protein S
- Platelets <100,000/µL
- Serum creatinine >1.8 mg/dL
- INR >3
- aPTT (or PTT) >50 seconds on no anticoagulation
- Systolic BP <90 mmHg for 15 min or the requirement of inotropic support to maintain systolic BP ≥90 mmHg
- FiO2 requirement >40% or >6 LPM to keep oxygen saturations >90%
- Hematocrit <28%
- Absolute contraindication to anticoagulation
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
- Known serious, uncontrolled sensitivity to radiographic agents
- Life expectancy <90 days, as determined by investigator
- Female who is pregnant
- Intracardiac thrombus
- Simultaneous participation in another investigational study
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United States
- Ascension St. John Jane Phillips Medical CenterBartlesville, United States
- University of CincinnatiCincinnati, United States
- Cleveland ClinicCleveland, United States
- Baylor Scott and White Heart and Vascular Hospital-DallasDallas, United States
- Janna, LLCFort Lauderdale, United States
- Vital Heart and VeinHumble, United States
- Ascension St. Vincent HospitalIndianapolis, United States
- University Medical Center of Southern NevadaLas Vegas, United States
- Baylor Scott & White The Heart Hospital - PlanoPlano, United States
- Baycare Health SystemTampa, United States
- ProMedica Toledo HospitalToledo, United States
- Medstar Health Research InstituteWashington D.C., United States
- UMass Chan Medical SchoolWorcester, United States
About the trial
What the trial wants to find out
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
The group in the trial
- Mechanical Thrombectomy via Cleaner ProTreatment being tested
Participants will receive catheter-directed therapy via mechanical aspiration thrombectomy for the treatment of pulmonary embolism (PE) using the Cleaner Pro Thrombectomy System.
Treatment: Cleaner Pro Thrombectomy System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective, Multicenter Study to Evaluate the Safety and Efficacy of an Aspiration Thrombectomy System in Acute Pulmonary Embolism
- Record updated
- 21 October 2026